The USFDA has approved palopegteriparatide to treat adults with hypoparathyroidism. Palopegteriparatide is a parathyroid hormone analog, and its safety and efficacy were determined in a phase 3 clinical trial.
Clinical evidence In the study conducted on 82 hypoparathyroidism patients, 68.9% of patients treated with palopegteriparatide attained normal levels of albumin-corrected serum calcium and required no active vitamin D and calcium supplementation at week 26 compared to 4.8% of patients in the placebo group. Dosage and administration Available as a single-patient-use prefilled pen Once daily, subcutaneous infection Maximus dosage: 30 mcg Warnings Palopegteriparatide can Cause severe hypercalcemia, hypocalcemia, and digoxin toxicity Increases the risk of osteosarcoma Adverse reactions – Vasodilatory signs and symptoms, back pain, headache, oropharyngeal pain, and diarrhea Did you…
